We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Fast Triple Test a Game Changer for Expectant Mothers

By LabMedica International staff writers
Posted on 24 Jul 2025

HIV/AIDS, Hepatitis B, and Syphilis continue to pose significant health threats across Africa, especially among pregnant women. More...

Testing for these infections is often fragmented and time-consuming, with Syphilis testing rates lagging behind those for HIV and Hepatitis B. In Rwanda, for example, while testing coverage exceeds 95% for HIV and Hepatitis B, Syphilis testing remains under 70% due to being offered separately. In Kenya, a study revealed that 95.3% of surveyed women had never been tested before, pointing to limited access to screening services. Prevalent stockouts of testing kits and reagents further exacerbate the problem, hindering timely and comprehensive diagnostics. Now, a single test that allows for the simultaneous detection of the three infections is expected to reduce the time patients spend in healthcare facilities and improve the efficiency of healthcare delivery across Africa.

Abbott (Abbott Park, IL, USA) has introduced the WHO-approved Determine Antenatal Care Panel (ANC Panel), a triple test kit that requires only a single finger prick and delivers results within 20 minutes. The development was guided by efforts to eliminate HIV/AIDS, Hepatitis B, and Syphilis by 2030 and improve healthcare efficiency across Africa. The ANC Panel combines the testing for all three infections into a single, streamlined process. The kit is expected to cut the average clinic visit time from 113 minutes to 39 minutes and ease the workload of healthcare staff. In Kenya, where the kit was evaluated, it significantly reduced wait times and improved access to care. Despite initial challenges in hepatitis testing compared to malaria, the ANC Panel demonstrated high accuracy and usability.

In the Kenyan study, 95% of women rated the triple test kit as reliable and accurate, underscoring its potential to improve diagnostics. Officials in Rwanda confirmed that the test aligns with national goals and ongoing triple elimination strategies. Though the test is currently targeted at women, it has also been used to test men in Kenya, and Rwandan authorities are exploring a similar inclusive approach. The rollout is expected to begin across several countries based on available funding and interest. Discussions with global partners are ongoing to support broader deployment. The ANC Panel may soon serve not just antenatal care, but also contribute to broader screening efforts among diverse populations.

Related Links:
Abbott


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Electrolyte Analyzer
BKE-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.